Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?

Our objective was to assess whether HIV-1 RNA levels provide additional prognostic information beyond CD4(+) T lymphocyte counts in the prediction of subsequent HIV-1 disease progression among patients with advanced HIV-1 disease. In a nested case-control study conducted in patients with baseline CD4(+) T lymphocyte counts < 300 cells/mm(3) and receiving nucleoside reverse transcriptase inhibitors, 102 patients who progressed to an AIDS-defining event or death were matched within 10 CD4(+) T lymphocyte cells/mm(3) to patients who did not progress. The relationship between plasma HIV-1 RNA levels and HIV-1 disease progression was studied using conditional logistic regression analysis, which adjusts for the matching by baseline CD4(+) T lymphocytes. We observed a 0.10 log(10) copies/ml difference in baseline HIV-1 RNA levels between cases and their matched controls (p = 0.027). The relative risk for HIV-1 disease progression increased with increasing baseline HIV-1 RNA levels (odds ratio [OR] for a 3-fold higher HIV-1 RNA level, 1.42; 95% confidence interval [CI], 1.08--1.86), and remained important when also controlling for clinical status at baseline and CD4(+) T lymphocytes at 2 months (p = 0.038). Higher baseline HIV-1 RNA levels were associated with HIV-1 disease progression among patients with a baseline CD4(+) T lymphocyte count of 100 cells/mm(3) or greater (OR, 1.80; 95% CI, 1.15--2.81), but not among patients with a baseline CD4(+) T lymphocyte count < 100 cells/mm(3) (OR, 1.09; 95% CI, 0.73--1.63). We concluded that HIV-1 RNA levels predict subsequent HIV-1 disease progression independent of CD4(+) T lymphocyte counts. The magnitude and importance of the prognostic information contained in the HIV-1 RNA levels appear to depend on the CD4(+) T lymphocyte counts.

[1]  S. Hammer,et al.  The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of ⩽ 50 × 106 cells/l , 2000, AIDS (London).

[2]  J. Goedert,et al.  Plasma HIV Viral Load in Patients with Hemophilia and Late-Stage HIV Disease: A Measure of Current Immune Suppression , 1999, Annals of Internal Medicine.

[3]  F Miedema,et al.  Normal telomere lengths in naive and memory CD4+ T cells in HIV type 1 infection: a mathematical interpretation. , 1999, AIDS research and human retroviruses.

[4]  G. Pantaleo,et al.  T cell regeneration in HIV-infected subjects under highly active antiretroviral therapy (review). , 1999, International Journal of Molecular Medicine.

[5]  M A Fischl,et al.  A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[6]  H. Ullum,et al.  The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection , 1998, AIDS.

[7]  T. Perneger,et al.  A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4 + Cell Counts in HIV-Infected Patients , 1998 .

[8]  I Spijkerman,et al.  AIDS prognosis based on HIV‐1 RNA, CD4+ T‐cell count and function: markers with reciprocal predictive value over time after seroconversion , 1997, AIDS.

[9]  M. Prins,et al.  Early and late HIV‐1 RNA level and its association with other markers and disease progression in long‐term AIDS‐free homosexual men , 1997, AIDS.

[10]  M. Hughes,et al.  Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.

[11]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[12]  J. Kahn,et al.  Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .

[13]  J. Kahn,et al.  Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.

[14]  J. Bartlett,et al.  HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. , 1996, AIDS.

[15]  T. Perneger,et al.  Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. , 1996, The Journal of infectious diseases.

[16]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[17]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[18]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[19]  C. Loveday,et al.  Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count , 1995, The Lancet.

[20]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[21]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[22]  R. Gelman,et al.  Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 1993, Cytometry.

[23]  A. Fauci,et al.  The immunopathogenesis of human immunodeficiency virus infection. , 1993, The New England journal of medicine.

[24]  J. Kagan,et al.  Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. , 1993, Clinical immunology and immunopathology.

[25]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[26]  D. Katzenstein,et al.  Inhibition of human immunodeficiency virus gene amplification by heparin , 1991, Journal of clinical microbiology.

[27]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[28]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[29]  Steven G. Deeks,et al.  Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans , 1999, Nature Medicine.

[30]  H. Schuitemaker,et al.  Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. , 1998, Immunology today.

[31]  S. Hammer,et al.  Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, The Journal of infectious diseases.

[32]  Ann Collier,et al.  Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease , 1995, Annals of Internal Medicine.